The P-III (DELIVER) trial evaluates Farxiga vs PBO in 6263 patients with HF with LVEF ≥40% with/out T2D & mildly reduced or preserved EF
The results showed an 18% vs 19.5% reduction in the composite outcome of CV death or worsening of HF with absolute risk reduction (3.1%) over a median follow-up of 2.3yrs. along with symptom benefits in PROs. Each individual component enhanced the superiority of the 1EPs
The safety & tolerability profiles were consistent with the well-established safety profile of Farxiga. The results were presented at ESC 2022 & published in the NEJM. The results complement the most recent treatment recommendations, advocating an earlier start of medical treatment. They may also promote broader use of SGLT2 inhibitors in clinical settings
Ref: Businesswire | Image: AstraZeneca
